Elevate Your Expertise in Diabetes Care
Joslin Diabetes Center presents:
The Severe Hypoglycemia Certificate Program
This exclusive opportunity is available for a short time and limited to 500 participants.
Acknowledgement: This e-learning program is sponsored by Gvoke HypoPen®. Content developed solely by Joslin Diabetes Center.
Why Should You Sign Up?
Recent updates to diabetes guidelines related to hypoglycemia highlight the urgent need to:
- Provide comprehensive education for patients and caregivers
- Ensure that hypoglycemia is addressed at each interaction2
- Ensure that individuals at high risk for hypoglycemia have access to ready-to-use glucagon, a potentially life-saving treatment1,2
The critical need for education and proactive measures to protect individuals at risk of hypoglycemia led to the development of The Severe Hypoglycemia Certificate Program.
This program provides the knowledge and tools you need to ensure that the at-risk patients you care for are protected according to the latest standards of care.
Joslin Diabetes Center: Excellence in Diabetes Education
Joslin Diabetes Center stands out as one of the few institutions wholly dedicated to diabetes.
As a leader in diabetes treatment, education and research, Joslin is nationally recognized for producing programs that significantly enhance educational outcomes. The Severe Hypoglycemia Certificate Program, crafted by their leading faculty, is no exception — it sets a standard for excellence.
Program Overview
The Severe Hypoglycemia Certificate Program delivers comprehensive information about hypoglycemia, guideline recommendations, and practical ways to implement these standards of care into practice.
| 1. | Hypoglycemia: A Limiting Factor for Optimal Management of Diabetes | 44 min |
| 2. | Hypoglycemia Management in the Ambulatory Setting: The Path to Guideline Implementation | 60 min |
| 3. | Putting Standards of Medical Care into Practice | 60 min |
| 4. | Diabetes Education and the Diabetes Care Plan | 34 min |
| 5. | Diabetes Education: Putting It All Together | 26 min |
| 6. | Hypoglycemic Management Using Novel Technologies | 32 min |
| 7. | Acute Hypoglycemic Emergencies and Hypoglycemia Management in the Inpatient Setting | 54 min |
What to expect
Expert-Led Content
Learn from the best with 7 modules crafted by leading faculty from Joslin Diabetes Center, renowned experts in diabetes care.
Flexible Learning
Enjoy the freedom to access online modules anytime, anywhere, and study at your own pace.
Elevate Patient Care
Stay ahead with the latest hypoglycemia guidelines and treatment options, equipping yourself with essential skills to protect at-risk patients.
Prestigious Certificate
Earn a coveted Joslin Diabetes Certificate of Completion, a testament to your dedication to advancing patient care and achieving excellence in diabetes management.
Act Now!
Questions?
For more information, contact us at SevereHypoProgram@xerispharma.com
or call (312) 736-1600
Acknowledgement: This e-learning program is sponsored by Gvoke HypoPen®. Content developed solely by Joslin Diabetes Center.
REFERENCES:
- McCall AL, Lieb DC, Gianchandani R, et al. Management of individuals with diabetes at high risk for hypoglycemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023;108(3):529-562. doi:10.1210/clinem/dgac596.
- American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S111–S125. doi.org/10.2337/dc24-S006.
INDICATION AND IMPORTANT SAFETY INFORMATION
GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.
IMPORTANT SAFETY INFORMATION
Contraindications
GVOKE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure, insulinoma because of the risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.
Warnings and Precautions
GVOKE is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.
In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GVOKE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously.
Allergic reactions have been reported with glucagon. These include generalized rash, and in some cases, anaphylactic shock with breathing difficulties and hypotension. GVOKE is contraindicated in patients with a prior hypersensitivity reaction.
GVOKE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia, may not have adequate levels of hepatic glycogen for GVOKE administration to be effective. Patients with these conditions should be treated with glucose.
Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported postmarketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.
Adverse Reactions
Most common (≥5%) adverse reactions associated with GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.
Drug Interactions
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE. In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin.
Please see the Full Prescribing Information for Gvoke.